(A) Immunohistochemistry of a liver section from a representative chimeric mouse showing FAH+ hepatocytes from ARSA-HA–transgenic donors repopulating the FAH–/– recipient. Scale bar: 20 μm. (B) Western blot analysis of liver samples from chimeric (nos. 17, 19, 23, and 26), control FAH+/– (Co), GT-treated (GT: 2 different animals), and transgenic mice. Blot hybridization with anti-HA antibody (upper panel) showed ARSA-HA expression in chimeric mice and detectable protein in the GT mouse. GAPDH hybridization was used for normalization (lower panel). The engraftment of ARSA-HA, FAH+ hepatocytes was quantified by the percentage of FAH+ cells on liver sections (C) and by ARSA-HA activity of liver samples, expressed as fold increase compared with FAH+/– levels (D). LV content in the liver is expressed in CpC (right y axes in C and D). (E) ARSA-HA activity was detected in the serum of GT and chimeric mice, indicating that the tagged enzyme was secreted into the bloodstream. (F–J) Confocal immunofluorescence and Western blot analysis of kidney (F and G), DRG (H), and brain (I and J) from representative mice. For Western blots, anti-HA hybridization is shown in the upper panels, anti-GAPDH in the lower panels, and MW markers on the right (in kDa). ARSA-HA signal was detected in the kidney and DRG of transgenic, GT, and chimeric mice. In contrast, the signal was detected only in the brain of transgenic and GT mice, not of chimeric mice, indicating that ARSA-HA could not reach the brain from the bloodstream. Scale bar: 20 μm.